Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

Item

http://www.wikidata.org/entity/Q28257174

Q28257174

about

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Trial Watch: Monoclonal antibodies in cancer therapy Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia Recent advances in targeted therapy of human myelogenous leukaemia.From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.Current therapeutic strategies for acute myeloid leukaemia.Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.Targeting cancer stem cells.Acute myeloid leukaemia: optimal management and recent developments.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies Antibody-based therapy of leukaemia.Construction and expression of a human/mouse chimeric CD19 monoclonal antibody: Successful modification of a murine IgM to a chimeric IgG.Acute myeloid leukaemia in the elderly: a review.What happened to anti-CD33 therapy for acute myeloid leukemia?New agents for acute myeloid leukemia: is it time for targeted therapies?Current strategies in immunotherapy for acute myeloid leukemia.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Antibody therapy for acute myeloid leukaemia.Monoclonal antibodies as therapeutics in human malignancies.Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia.Immunotherapy in acute myeloid leukemia.Emerging therapeutic drugs for AML.Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Gemtuzumab ozogamicin in acute myeloid leukemia.Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

P2860

Q33401218-3BCD024E-DA8D-43B4-B1EF-612218BC0655 Q33849537-BE7B7339-43E4-4435-8C2D-C786A85B8476 Q33903030-B9BE569D-CA83-4856-947A-6D55FD8C4A78 Q34268110-B0B83505-5CFD-4B31-A2BE-E3D3B63DA4D4 Q34769652-8398CD4E-F994-45BA-9574-861CA5546F1F Q35146288-9014ED32-8730-42E7-AEE7-3DF9AAAA060F Q35546759-0D831A7A-6114-4AF8-8CA8-DE93774CF00F Q36038408-591CC228-6744-4450-9865-FC0A6EF220AF Q36049914-46F07C18-1BA6-4BBD-BA77-A637309EA936 Q36318531-FFE3E420-EE03-4BB4-9951-40BA47B0523C Q36352100-08FC5207-116B-4F97-B25F-44E4F7863C6A Q36429727-213EB9A1-360F-4183-A55C-1C9C0B93BC44 Q36498399-FEF10B84-9CB2-4501-86C0-D9BFA4B85B77 Q36539598-7C68B95D-7C6E-4454-84B0-8FA23376A0F4 Q36770191-F5E15661-26DA-45E4-ABBB-A6CA2183984B Q36871985-E87D069B-42B0-42D3-A8AE-426F28033C71 Q36914091-B93C7E09-E737-47EF-871E-5FFE9B95EDEC Q36932014-C46840DE-1927-42B6-89DF-EF80B8501F8B Q36961604-39FD5C2B-409C-4022-A09F-1AEBE9D4FF70 Q36979140-8361776B-D48F-46E3-9B9A-6AA5657AF351 Q36989586-1728098F-3C85-4F4A-8DE1-714080E519FF Q37174938-0CB85BA3-B4DB-4E09-AF37-B0E222627371 Q37221579-1A70A93C-5168-4084-AFB7-AFD1044736FB Q37340948-A96AE561-767A-4ACA-8158-20007C680E1E Q37605247-DDE7701D-9906-4674-844A-A2A3CD5ED65F Q37652075-AB162435-37B0-4ACC-AAC5-C0794084F102 Q37840260-D2857339-7B63-41AB-8F17-2981F8E1200E Q37959880-F3826C9C-5C2F-4DE7-A019-7CE32AB86E9E Q37973135-37C760D7-8815-423A-99E8-04BF9AFAF86B Q38068967-C491C06A-D52D-43B9-83A5-FB768A187234 Q38155455-9371B8A1-830A-446A-9A02-4894CB9788F3 Q38169814-BC0C2FC4-8DD8-4D81-AF24-BB6B67E10D7F Q38206275-418C64DE-1CD6-4AEF-9E75-858D41CD7F2F Q38256888-1C50D39B-ECB4-4D93-8E3C-0AE30A7FE408 Q38533606-F68D9942-2DFC-4573-8F31-0F80C682FD39 Q38667491-8A3D78A7-CF24-453B-9430-B1E94704508A Q38700209-FB716F3A-A696-4D92-B90B-78A1E4AD96F4 Q38728718-7A6EC545-604C-48AA-938E-E4F174F1CFFD Q38759754-CF5EE993-1388-41CC-9F2D-0A9D380370E8 Q38891877-2F8D2A3F-4D9E-4FB2-830A-92A28C6B4563

P2860

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

Item

http://www.wikidata.org/entity/Q28257174

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu